National Report Card, Abstracts & Posters

We would like to thank Red Maple Trials (RMT), staff at Yang Medicine and the HAE Canada Advocacy Committee and Board of Directors for the amazing job they have done creating these abstracts and posters for HAE Canada. We are grateful we can collaborate with this fantastic team.

A special thank you goes to Dr. William Yang for his endless dedication to HAE patients and his very valued advice and availability to HAE Canada. We wouldn’t be the Patient Organization we are today without his expertise.

Our  2017 National Report Card was presented at the HAEi’s 2018 HAE Global Conference, CSACI Scientific Meeting 2018 in Halifax, AAAAi Annual Meeting 2019 in San Francisco, 2019 European Academy of Allergy & Clinical Immunology (EAACI) Congress in Lisbon & at the CSL Behring Conference for the 40th Anniversary of C1-INH in Marburg, Germany in August 2019:

**NEW** Data from the 2017 National Report Card survey was used to develop an additional abstract and poster; both were presented at the 2021 Virtual AAAAi Annual Meeting:

  • National Report Card: Real World Data (Health Economic Burden): Abstract and Poster

CSACI: Canadians living with HAE: Attributes of new medications: Abstract & Poster  (June 2019)

Takeda’s HAE Global Forum Poster: Real World Data of Canadians Living with HAE: Attributes of New Medications  presented in Berlin, Germany (November 2019)

HAEi’s HAE Global Abstract & Slide Show Presentation: Fear of Attacks Reduces Quality of Life for Canadian HAE Patients (May 2020)

EAACI Abstract & Poster: Real-world data of Canadians living with HAE: Need for Innovative, Newer Prophylactic and Subcutaneous Treatments  (June 2020)  **We are proud to report that the Poster was awarded a Five Star Rating by Dr. Marcus Maurer at the EAACI Digital Congress held on June 6, 2020**

HAE Canada collaborated with the Canadian HAE Network (CHAEN) on two presentations for the JSA / WAO Joint Congress 2020 titled:  Assessment of HAE-specific Quality of Life and Proximity to Acute Therapy and Prodromes and Attack Triggers in Canadian HAE Patients